EFFICACY AND SAFETY

Patient reported outcomes in ATLAS-2M

98% of trial patients preferred every 2-month dosing to daily oral therapy at 48 weeks(secondary end-point)

During the ATLAS-2M trial, patients reported a high preference for every 2-month dosing over daily oral dosing.1,2 Some patients found long-acting treatment to be more convenient while others expressed not having to worry about storing their daily medication.3

Patients on long-acting therapy were asked: Based on your experience, which HIV treatment do you prefer?4,5
PATIENT-REPORTED OUTCOME RESULTS ON PREFERENCE, WITHOUT PRIOR EXPOSURE TO LONG-ACTING THERAPY (secondary endpoint)6
Patient reported outcome results on preference without prior exposure in ATLAS-2M trial
300 patients in ATLAS-2M were asked what aspects of Every 2-Month VOCABRIA + REKAMBYS they preferred:
78% icon

found 2-month dosing to be more convenient and easier to integrate into their daily life3

58% icon

preferred the frequency of administration3

MOST TRIAL PATIENTS WITH PRIOR EXPOSURE TO LONG-ACTING THERAPY PREFERRED EVERY 2-MONTH DOSING TO MONTHLY DOSING6
Patient reported outcome results on preference with prior exposure in ATLAS-2M trial

The patient experience

Understanding the impact of long-acting therapy

*Mark and Orlando are clinical trial participants from the ATLAS study reporting on their experiences with Monthly VOCABRIA + REKAMBYS. They have given consent for use of their images and words and received remuneration from ViiV Healthcare.

ARV=antiretroviral.

References:

  1. VOCABRIA Summary of Product Characteristics. ViiV Healthcare.
  2. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0.
  3. Data on file. ATLAS-2M Week 48 CSR. REF 87287.ViiV Healthcare group of companies.
  4. Data on file. Preference questions ATLAS-2M. REF 73480. ViiV Healthcare group of companies.
  5. Data on file. Preference questions ATLAS-2M. REF 100660. ViiV Healthcare group of companies.
  6. Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. Published online ahead of print: December 9, 2020. doi: 10.1016/S0140-6736(20)32666-0. Supplementary material.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

REKAMBYS (rilpivirine long acting injection), including the trademark is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.

PM-GB-CBR-WCNT-210001v3 I April 2022

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.